Withaferin A shows anticancer activity in pancreatic cancer cell lines and in vivo pancreatic cancer xenografts via inhibition of Hsp90 in an ATP-independent manner which induces protein degradation and disrupts the Hsp90-Cdc37 interaction (Yu et al., 2010a). Here, CDC37 is linked to pancreatic neoplasm.